Already a Bloomberg.com user?
Sign in with the same account.
Kamada Ltd. (KMDA) rose to the highest level in almost six months after the biopharmaceutical company said initial results from Phase I and II clinical trials on a drug to treat juvenile diabetes showed a positive trend.
The shares advanced 3.8 percent to 24.19 shekels at 10:48 a.m. in Tel Aviv, the highest level since Oct. 27, giving the Nes Ziona-based company a market value of 668 million shekels ($178 million).
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org